scholarly journals Albuminuria in Type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians

Diabetologia ◽  
1989 ◽  
Vol 32 (12) ◽  
pp. 870-876 ◽  
Author(s):  
R. G. Nelson ◽  
C. L. Kunzelman ◽  
D. J. Pettitt ◽  
M. F. Saad ◽  
P. H. Bennett ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Pima Indians ◽  
Insulin Dependent

scholarly journals Epidemiology of diabetes mellitus in relation to other cardiovascular risk factors in Lebanon

1997 ◽  
Vol 3 (3) ◽  
pp. 462-471
Author(s):  
Ibrahim S. Salti ◽  
Mustafa Khogali ◽  
Samir Alam ◽  
Najib Abu Haidar ◽  
Amal Masri
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Main Risk Factor ◽  
Serum Triglycerides ◽  
Insulin Dependent

A study of 2518 Lebanese subjects [1138 males, 1380 females] aged 30 years and over revealed an overall prevalence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance of 13.1% and 6.0% respectively. The prevalence of non-insulin-dependent diabetes mellitus was similar in both sexes, while impaired glucose tolerance was slightly higher among females;both increased steadily with age. The main risk factor was obesity [55% in males, 67% in females]. Participants with diabetes and impaired glucose tolerance were more likely to have heart disease, and had slightly higher blood pressure and serum triglycerides

Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats

1995 ◽  
Vol 73 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Hideki Ohnota ◽  
Takashi Koizumi ◽  
Miho Kobayashi ◽  
Fumiyasu Sato ◽  
Yasunori Momose
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Tolerance ◽  
Oral Administration ◽  
Impaired Glucose Tolerance ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Short Acting ◽  
Hypoglycemic Agent ◽  
Insulin Dependent

We have investigated the hypoglycemic effects of the newly synthesized short-acting nonsulphonylurea hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinyicarbonyl)-propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus (NIDDM) rats. NIDDM rats that were given a neonatal injection of 60 mg/kg streptozotocin showed a dose-dependent but attenuated response to oral administration of KAD-1229 and gliclazide, and their impaired glucose tolerance was improved but not normalized. We next produced, using a neonatal injection of 30 mg/kg streptozotocin, a mild type of NIDDM rat with less impaired glucose tolerance. These rats responded well to these insulinotropic hypoglycemic agents. Their impaired glucose and meal tolerance were completely normalized by oral administration of 3 mg/kg KAD-1229. The efficacy of KAD-1229 in this NIDDM rat model 1–3 h after oral glucose administration was comparable with similar doses of gliclazide, despite its shorter hypoglycemic action (compared with gliclazide), in fasting normal rats. In meal tolerance tests (20 kcal/kg; 1 cal = 4.2 J), KAD-1229 reduced abnormally enhanced plasma glucose levels 1–3 h after administration. This effect disappeared by 5 h. In contrast, gliclazide showed sustained hypoglycemic effects until 5 h after oral administration, with a lower postprandial (0.5–1 h) effect. These data indicated that the rapid- and short-acting efficacy of KAD-1229 would be beneficial and sufficient to control postprandial plasma glucose in NIDDM rats.Key words: KAD-1229, hypoglycemic agent, streptozotocin-induced non-insulin-dependent diabetes mellitus rats.

Sign in / Sign up

Export Citation Format

Share Document